
Boryung ignites BR2002’s phase 1 clinical trial in US The Investor
South Korea’s Boryung Pharmaceutical announced on Aug. 27 it had received approval from the US Food and Drug Administration to start a phase 1 clinical trial …
“lymphoma cancer” – Google News
